HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol. METHODS: A post hoc analysis of the recently completed Treating to New Targets (TNT) study assessed the predictive value of HDL cholesterol levels in 9770 patients. The primary outcome measure was the time to a first major cardiovascular event, defined as death from coronary heart disease, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. The predictive relationship between HDL cholesterol levels at the third month of treatment with statins and the time to the first major cardiovascular event was assessed in univariate and multivariate analyses and was also assessed for specific LDL cholesterol strata, including subjects with LDL cholesterol levels below 70 mg per deciliter (1.8 mmol per liter). RESULTS: The HDL cholesterol level in patients receiving statins was predictive of major cardiovascular events across the TNT study cohort, both when HDL cholesterol was considered as a continuous variable and when subjects were stratified according to quintiles of HDL cholesterol level. When the analysis was stratified according to LDL cholesterol level in patients receiving statins, the relationship between HDL cholesterol level and major cardiovascular events was of borderline significance (P=0.05). Even among study subjects with LDL cholesterol levels below 70 mg per deciliter, those in the highest quintile of HDL cholesterol level were at less risk for major cardiovascular events than those in the lowest quintile (P=0.03). CONCLUSIONS: In this post hoc analysis, HDL cholesterol levels were predictive of major cardiovascular events in patients treated with statins. This relationship was also observed among patients with LDL cholesterol levels below 70 mg per deciliter. (ClinicalTrials.gov number, NCT00327691 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies have shown that HDL cholesterol (HDL-C) levels under statin treatment remain an independent predictor of the risk of cardiovascular events in patients who have been treated with statins to lower LDL-C levels4”
From MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice (2012) · cites this paper as [4]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.151”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [151]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [292]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Self-citationDowns, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- 10.1001/jama.251.3.351 · DOI · Paper page
Cited by
Items 901–1,000 of 1,001
Barter (2011) · doi:10.1016/s1567-5688(11)00035-3 · Cited by 10
Lee, W., Kim, J. H., Park, S. E., Park, C. ‐., Oh, K.-W., Park, S.-W., Rhee, E., & Lee, W. (2017) · Archives of Medical Research · doi:10.1016/j.arcmed.2017.06.005 · Cited by 9
Li, C., Grove, M. L., Yu, B., Jones, B. C., Morrison, A. C., Boerwinkle, E., & Liu, X. (2017) · Human Genetics · doi:10.1007/s00439-017-1858-8 · Cited by 10
“2001), low high-density lipoprotein (HDL) cholesterol, and high low-density lipoprotein (LDL) cholesterol levels (Barter et al. 2007).”
Manita, D., Yoshida, H., & Hirowatari, Y. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.34728 · Cited by 12
Low plasma HDL‐c, a vascular risk factor in high risk patients independent of LDL‐c
Hajer, G. R., van der Graaf, Y., Bots, M. L., Algra, A., Visseren, F. L. J., & on behalf of the SMART Study Group (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02155.x · Cited by 11
Luo, L., Dai, D., Zheng, Y., & Dai, Y. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp/61.06.0010 · Cited by 10
Rosenson, R. S., & Brewer, H. B. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6576-7 · Cited by 10
High-density lipoprotein cholesterol targeting for novel drug discovery: where have we gone wrong?
Escolá‐Gil, J. C., Cedó, L., & Blanco‐Vaca, F. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.871257 · Cited by 12
Maadani, M., Sarraf, N. S., Alilou, S., Aeinfar, K., Sadeghipour, P., Zahedmehr, A., Fathollahi, M. S., Ghadi, S. I. H., Zavarehee, A., Zolfaghari, M., et al. (2022) · Texas Heart Institute Journal · doi:10.14503/thij-20-7384 · Cited by 14
Lee, G., Kang, K., Yun, H. H., Jo, W., & Oh, T. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13597 · Cited by 13
Mohammadi, F., Yadegar, A., Rabizadeh, S., Ayati, A., Seyedi, S. A., Nabipoorashrafi, S. A., Esteghamati, A., & Nakhjavani, M. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02010-6 · Cited by 16
Kakuda, H., Matoba, M., Nakatoh, H., Nagao, S., & Takekoshi, N. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.07.007 · Cited by 10
Residual Risk and High-Density Lipoprotein Cholesterol Levels: Is There a Relationship?
Shah, P. K. (2011) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0565 · Cited by 9
Kim, S. J., Han, K., Jang, S., & Park, E. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.08.016 · Cited by 9
Toth, P. P., Jones, S. R., Slee, A. E., Fleg, J. L., Marcovina, S. M., Lacy, M., McBride, R., & Boden, W. E. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.03.077 · Cited by 10
High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?
von Eckardstein, A. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_536 · Cited by 13
Mun, S., Jang, C. J., Jo, S. B., Park, S.-H., Sim, H. B., Ramos, S., Kim, H. J., Choi, Y.-J., Park, D.-H., Park, K.-W., et al. (2024) · Animal Cells and Systems · doi:10.1080/19768354.2024.2374547 · Cited by 10
Acharya, S., Liao, S., Jung, W. J., Kang, Y. S., Moghaddam, V. A., Feitosa, M. F., Wojczynski, M. K., Lin, S. J., Anema, J. A., Schwander, K., et al. (2024) · Human Genetics · doi:10.1007/s00439-024-02701-1 · Cited by 9
Laitinen, D. L., & Manthena, S. R. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0019-4 · Cited by 9
Induction of P450 3A1/2 and 2C6 by gemfibrozil in Sprague-Dawley rats
Liu, A., Yang, J., Zhao, X., Jiao, X., Zhao, W., Ma, Q., Tang, Z., & Dai, R. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70410-8 · Cited by 9
Significance of High HDL Cholesterol Levels in Japanese Men with Metabolic Syndrome
Hiratsuka, N., Yamada, C., Mitsuhashi, T., Inabe, F., Araida, N., & Takahashi, E. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.5492 · Cited by 10
Pan, J., Gao, F., Bao, Y., Zhang, L., Tu, Y., & Jia, W. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.01.008 · Cited by 10
Comparative cardiometabolic effects of fibrates and omega-3 fatty acids
Han, S. H., Oh, P. C., Lim, S. K., Eckel, R. H., & Koh, K. K. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.01.223 · Cited by 11
“Even with the aggressive reduction of LDL-C, a high residual risk of cardiovascular events remains substantially and attracts attention to the need for additional preventive therapies [6,7].”
BackgroundTreating low high-density lipoprotein cholesterol: what is the evidence?
Hage, M. P., & Azar, S. T. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018813517522 · Cited by 10
Anacetrapib, a cholesteryl ester transfer protein inhibitor
Hooper, A., & Burnett, J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.642499 · Cited by 10
Cardiovascular Risk Factors in Gastric Cancer Patients Decrease 1 Year After Gastrectomy
Ha, T. K., Seo, Y. K., Kang, B.-K., Shin, J., & Ha, E. (2016) · Obesity Surgery · doi:10.1007/s11695-016-2085-4 · Cited by 10
Wu, D., Wu, Y.-X., & Deng, J.-L. (2020) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029620920369 · Cited by 9
Shimano, S., Ohkawa, R., Nambu, M., Sasaoka, M., Yamazaki, A., Fujii, Y., Horiuchi, Y., Lai, S.-J., Kameda, T., Ichimura, N., et al. (2021) · BioMed Research International · doi:10.1155/2021/9241259 · Cited by 9
Abudukeremu, A., Huang, C., Li, H., Sun, R., Liu, X., Wu, X., Xie, X., Huang, J., Zhang, J., Bao, J., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.700233 · Cited by 12
“(2) HDL particles that fail to perform the biological functions mentioned above are termed “dysfunctional.”
BackgroundMethodSuto, A., Yamasaki, M., TAKASAKI, Y., Fujita, Y., Abe, R., SHIMIZU, H., Ohta, H., & Takiguchi, M. (2013) · Journal of Veterinary Medical Science · doi:10.1292/jvms.13-0098 · Cited by 9
Cardiovascular risk in obese patients with chronic periodontitis: a clinical controlled study
Pires, J. R., Dezem, T. U., Barroso, E. M., de Toledo, B. E. C., Monteiro, S. C. M., Martins, A. T., & Zuza, E. P. (2013) · Revista de Odontologia da UNESP · doi:10.1590/s1807-25772013000300008 · Cited by 9
Liu, A., Xie, S., Sun, H., Gonzalez, F. J., Wei, X., & Dai, R. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.12.015 · Cited by 10
A Model of Lipid-Free Apolipoprotein A-I Revealed by Iterative Molecular Dynamics Simulation
Zhang, X., Lei, D., Zhang, L., Rames, M. J., & Zhang, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120233 · Cited by 9
Association between HDL-C concentration and risk for a major cardiovascular event
Laitinen, D. L., Manthena, S. R., & Webb, S. F. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003656968 · Cited by 10
Anamthathmakula, P., Jeyakumar, S. M., Giridharan, N. V., & Vajreswari, A. (2014) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.22186 · Cited by 9
Poulakou, M. V., Paraskevas, K. I., Vlachos, I. S., Karabina, S.-A. P., Wilson, M. R., Iliopoulos, D., Tsitsilonis, S., Mikhailidis, D. P., & Perrea, D. N. (2008) · Angiology · doi:10.1177/0003319707311722 · Cited by 9
“There is evidence that levels of HDL-C remain predictive of outcome within statin trials despite achieving a substantial fall in HDL-C levels.(27,44) Some of this benefit may be related to actions on the HDL-C-related apo J and PON1.”
BackgroundKoopal, C., van der Graaf, Y., Asselbergs, F. W., Westerink, J., & Visseren, F. L. J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.08.015 · Cited by 10
“Initially we hypothesized that presence of the CETP SNP rs3764261 would reduce the risk of recurrent CVD events in patients with a prior history of CVD due to an increase in HDL-C plasma levels [30,31].”
BackgroundLipid parameters in patients with acute coronary syndromes versus stable coronary artery disease
Vonbank, A., Saely, C. H., Rein, P., & Drexel, H. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12513 · Cited by 9
F2-Isoprostanes in HDL are bound to neutral lipids and phospholipids
Proudfoot, J. M., Barden, A. E., Croft, K. D., Galano, J., Durand, T., Bultel‐Poncé, V., Giera, M. A., & Mori, T. A. (2016) · Free Radical Research · doi:10.1080/10715762.2016.1250262 · Cited by 9
Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies
Yvan‐Charvet, L., & Cariou, B. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000505 · Cited by 10
Attanayake, A., Jayatilaka, K., Mudduwa, L., & Pathirana, C. (2018) · Journal of Botany · doi:10.1155/2018/4204519 · Cited by 9
“Cardioprotective index (CPI)was estimated in terms ofHDLC to LDL-C ratio, whereas atherogenic (AI) and coronary risk indices (CRI) were calculated by the following formulae [25]: AAI = [TC-HDL-C]/[HDL-C]”
Ruiz‐García, A., Arranz-Martínez, E., Merchante, I. M., Fuster, V. P., Tamarit, J. J., Trias, F., Pintó, X., & Ascaso, J. F. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.06.006 · Cited by 14
Kappelle, P. J. W. H., Zwang, L., Huisman, M. V., Banga, J. D., Sluiter, W. J., Dallinga‐Thie, G. M., & Dullaart, R. P. F. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903023866 · Cited by 9
Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?
Athyros, V. G., Kakafika, A. I., Τζιόμαλος, Κ., Karagiannis, A. I., & Mikhailidis, D. P. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.4.445 · Cited by 9
Kini, A. S., Muntner, P., Moreno, P., Mann, D., Krishnan, P., Kim, M. C., Rafael, O. C., Farkouh, M. E., & Sharma, S. K. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.087 · Cited by 9
Belsey, J., de Lusignan, S., Chan, T., van Vlymen, J. N., & Hague, N. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802321964 · Cited by 10
Cardiovascular protection for all individuals at high risk: evidence-based best practice
Bakris, G. L., Böhm, M., Dagenais, G. R., Diener, H., Fujita, T., Gorelick, P. B., Kjeldsen, S. E., Laakso, M., Mancia, G., Pitt, B., et al. (2008) · Clinical Research in Cardiology · doi:10.1007/s00392-008-0713-2 · Cited by 9
Pfeffer, M. A., & Sacks, F. M. (2008) · Circulation · doi:10.1161/circulationaha.108.821512 · Cited by 9
Masky, B., Hamadjida, A., Miaffo, D., Oumarou, B.-F. A., Foyet, H. S., Maguirgue, K., Rodrigue, T. E., Bello, A. K., Bonabé, C., & Ntchapda, F. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100288 · Cited by 11
“The coronary risk index (CRI) was calculated using the formula of Barter and al [24].”
MethodFranczyk, B., Młynarska, E., Rysz-Górzyńska, M., Gluba-Brzózka, A., Rysz, J., Sheth, S., Surma, S., Banach, M., & Toth, P. P. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101068 · Cited by 10
“Clearly a significant number of prospective longitudinal cohorts suggested that low levels of HDL-C are a significant risk factor for cardiovascular events, even after adjustment for age, sex, LDL-C, and other ASCVD risk factors [2,66,133,134].”
A new look at HDL in coronary disease: can we escape natural history?
Gielen, S., & Landmesser, U. (2011) · Heart · doi:10.1136/heartjnl-2011-300612 · Cited by 8
Antisense oligonucleotides in the treatment of lipid disorders: pitfalls and promises.
Besseling, J., Hovingh, G. K., & Stroes, E. S. G. (2013) · PubMed · Cited by 9
Iheagwam, F. N., Iheagwam, O. T., Ogunlana, O. O., & Chinedu, S. N. (2023) · Gene Expression · doi:10.14218/ge.2023.00053 · Cited by 8
Dislipidemia diabética, macro y microangiopatía
Pedro‐Botet, J., Benaiges, D., & Pedragosa, À. (2012) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2012.09.005 · Cited by 14
Holme, I., Fellström, B., Jardine, A. G., & Holdaas, H. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.06.020 · Cited by 8
The relation between glycemic control and HDL-C in type 2 diabetes: a preliminary step forward?
Barbarossa, G., Renzi, A., D’Erasmo, L., Gallo, A., Grieco, E., Rossetti, M., Carnovale, A., Santilli, M., Mandosi, E., Coletta, P., et al. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.12.061 · Cited by 8
“In this context, recent evidence has emphasized the important association between low levels of HDL-C and increased CV risk [2].”
BackgroundHigh Density Lipoprotein Cholesterol in Coronary Artery Disease: When Higher Means Later
Sbrana, F., Puntoni, M., Bigazzi, F., Landi, P., Sampietro, T., Rossi, G., & Rovai, D. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.13201 · Cited by 9
Xia, J., Li, L., Ren, W., Zheng, X., Liu, C., Li, J., Chen, T., Li, X., Wang, L., & Hu, Y. (2015) · Europe PMC (PubMed Central) · Cited by 8
Hubungan Kadar Kolesterol Total dengan Tekanan Darah pada Masyarakat Jatinangor
Ulfah, M., Sukandar, H., & Afiatin, A. (2017) · Jurnal Sistem Kesehatan · doi:10.24198/jsk.v3i2.15004 · Cited by 8
Wadowski, P. P., Lee, S., Kopp, C. W., Koppensteiner, R., Panzer, S., & Gremmel, T. (2018) · Angiology · doi:10.1177/0003319718760074 · Cited by 10
Management of dyslipidaemias in the elderly population—A narrative review
Anagnostis, P. G., Vaitsi, K., Veneti, S., Georgiou, T., Paschou, S. Α., Lambrinoudaki, I. V., & Goulis, D. G. (2019) · Maturitas · doi:10.1016/j.maturitas.2019.03.011 · Cited by 10
Isdadiyanto, S., Sitasiwi, A. J., & Mardiati, S. M. (2020) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1524/1/012126 · Cited by 9
HDL Function across the Lifespan: From Childhood, to Pregnancy, to Old Age
Hong, B. V., Zheng, J., & Zivkovic, A. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015305 · Cited by 14
EASD, E. (2013) · Kardiologia Polska · doi:10.5603/kp.2013.0289 · Cited by 13
Lipoprotein (a): Perspectives from a lipid-referral program
Rubenfire, M., Vodnala, D., Krishnan, S. M., Bard, R. L., Jackson, E. A., Giacherio, D. A., & Brook, R. D. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.06.009 · Cited by 8
Clinical Insights From the Treating to New Targets Trial
Waters, D. D. (2009) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2009.01.001 · Cited by 9
The importance of considering alternative or combination strategies for lowering LDL-C
Koh, K. K., & Quon, M. J. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2009.03.035 · Cited by 8
Hosojima, M., Kaseda, R., Kondo, H., Fujii, M., Kubota, M., Watanabe, R., Tanabe, N., Kadowaki, M., Suzuki, Y., & Saito, A. (2016) · BMC Nutrition · doi:10.1186/s40795-016-0065-7 · Cited by 9
24. Cholesterol and vitamin D: how the ‘mother’ and ‘daughter’ molecules interact
Nkooyeh, B., & Neyestani, T. R. (2016) · Wageningen Academic Publishers eBooks · doi:10.3920/978-90-8686-821-6_24 · Cited by 9
Idoko, A. (2018) · Universal Journal of Pharmaceutical Research · doi:10.22270/ujpr.v3i1.r7 · Cited by 10
Mukai, J., Yoshiyama, A., & Kubota, R. (2020) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-020-00160-0 · Cited by 8
Ascaso, J. F., Millán, J., Hernández‐Mijares, A., Blasco, M., Brea, Á., Rodríguez, Á. D., Pedro‐Botet, J., & Pintó, X. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.11.004 · Cited by 14
Roberts, C. K. (2014) · CRC Press eBooks · doi:10.1201/b16783-5 · Cited by 8
Factors Associated with Recurrent Coronary Events Among Patients with Cardiovascular Disease
McConnell, K. J., Olson, K. L., Delate, T., & Merenich, J. A. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.8.906 · Cited by 8
Merkel, M. (2012) · Der Diabetologe · doi:10.1007/s11428-012-0889-y · Cited by 8
HDL-C: Helpful, harmful, hopeful, or guilty by association
McLean, P., Mathew, D., Chandrasekhar, S. A., Guynn, N., Razavi, A. C., Quyyumi, A. A., Mehta, A., & Sperling, L. S. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.09.017 · Cited by 7
Naim, M. A. A. Z., Sumida, K., Streja, E., Thomas, F., Davis, R. L., Kalantar‐Zadeh, K., & Kovesdy, C. P. (2026) · Drugs · doi:10.1007/s40265-025-02275-w · Cited by 8
Banach, M., Surma, S., Dzida, G. J., Jozwiak, J. J., Okopień, B., Rysz, J., Szosland, K., & Grzybowski, A. E. (2024) · Archives of Medical Science · doi:10.5114/aoms/197331 · Cited by 16
Miyares, M. A., & Davis, K. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s29010 · Cited by 12
Wang, C., Li, Y., Li, L., Wang, L., Zhao, J., You, A.-G., Guo, Y., & Li, W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049347 · Cited by 7
RetractedClinical and Biological Relevance of Statin-Mediated Changes in HDL Metabolism
Arsenault, B. J., & Boekholdt, S. M. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0379-8 · Cited by 8
Aterogénica, P. E. D. E. V. E. D. G. D. T. S. D. (2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.12.001 · Cited by 11
Kou, H., Shen, L., Luo, H.-W., Chen, L., Wu, D., & Wang, H. (2017) · Reproductive Toxicology · doi:10.1016/j.reprotox.2017.09.003 · Cited by 7
de Freitas, M. C. P., Neto, A. M. F., & Damasceno, N. R. T. (2020) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2020.101689 · Cited by 7
Norimatsu, K., Gondo, K., Kusumoto, T., Motozato, K., Suematsu, Y., Fukuda, Y., Kuwano, T., & Miura, S. (2020) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2020.1825725 · Cited by 7
Ruiz‐García, A., Arranz-Martínez, E., García-Fernández, M. E., Cabrera-Vélez, R., García-Pliego, R. A., Morales-Cobos, L. E., Sanz-Pozo, B., Gómez-Díaz, E., Rodríguez-de-Mingo, E., Rico-Pérez, M. R., et al. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.06.006 · Cited by 8
Ofori, E. K., Adekena, C. N., Boima, V., Asare‐Anane, H., Yorke, E., Nyarko, E. N. Y., Mohammed, B. N., Quansah, E., Jayasinghe, S. U., & Amanquah, S. D. (2023) · Health Science Reports · doi:10.1002/hsr2.1053 · Cited by 20
HDL Function and Size in Patients with On-Target LDL Plasma Levels and a First-Onset ACS
Cordero, A., Muñoz‐García, N., Padró, T., Vilahur, G., Bertomeu‐González, V., Escribano, D., Flores, E., Zuazola, P., & Badimón, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065391 · Cited by 7
The Impact of Testosterone Therapy on Cardiovascular Risk Among Postmenopausal Women
Britton, R. C., & Beamish, N. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad132 · Cited by 10
Lee, Y.-C., Chien, K., Lee, B., Lin, H.-J., Hsu, H., & Chen, M.-F. (2009) · Circulation Journal · doi:10.1253/circj.cj-09-0209 · Cited by 7
Ibuki (2012) · Journal of Clinical Medicine Research · doi:10.4021/jocmr1108w · Cited by 7
Rodríguez, F., Santos, R. D., Messig, M., Tarasenko, L. C., Ferrières, J., Jukema, J. W., Chiang, C.-W., Waters, D. D., & Foody, J. M. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.02.018 · Cited by 7
Tian, L., Chen, Y., Li, C., Zeng, Z., Xu, Y., Long, S., & Fu, M. (2012) · Lipids · doi:10.1007/s11745-012-3750-6 · Cited by 7
Imaging Progression of Coronary Atherosclerosis: Lessons Learned and Ongoing Challenges
Nicholls, S. J., Andrews, J., Puri, R., Uno, K., & Kataoka, Y. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-1337 · Cited by 8
Stein, J. H. (2016) · Europe PMC (PubMed Central) · Cited by 9
Ong, K. L., Waters, D. D., Fayyad, R. S., Vogt, L., Melamed, S., DeMicco, D. A., Rye, K., & Barter, P. J. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007387 · Cited by 9
Self-citationLi, Y., Tseng, W., Yin, W., Lin, F., Wu, Y., Hsieh, C., Lin, T., Sheu, W. H., Yeh, H., Chen, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78828-8 · Cited by 8
Cardiovascular Risk Study: A Comparison Between Northeast Ohio Cardiovascular Nurses and the Nation
Burns, K., Gross, B. J., & Zanin, M. (2010) · Journal of Community Health Nursing · doi:10.1080/07370016.2010.515452 · Cited by 7
“In fact, for each 1 mg/dl increase in HDL cholesterol, there is a 2% to 3% reduction in the risk of CHD (Barter et al, 2007).”
BackgroundUnniachan, S., Bash, L. D., Khovidhunkit, W., Sri, R., Vicaldo, E., Recto, C. S., & Ambegaonkar, B. M. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12407 · Cited by 7
Ota, T., Ishii, H., Suzuki, S., Shibata, Y., Tatami, Y., Harata, S., Shimbo, Y., Takayama, Y., Tanaka, A., Kawamura, Y., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.012 · Cited by 5
Metadata
- Authors
- Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C.
- Affiliations
- The Heart Research Institute (AU)
- Cornell University (US)
- SUNY Downstate Health Sciences University (US)
- Pfizer (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Alabama (US)
- Institut Pasteur de Lille (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-09-27
- Volume
- 357
- Issue
- 13
- Pages
- 1301-1310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158057499
- Cited by
- 1,610
- References
- 24
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 34 · 2023: 48 · 2022: 36 · 2021: 51 · 2020: 79 · 2019: 72 · 2018: 59 · 2017: 75 · 2016: 90 · 2015: 106 · 2014: 128 · 2013: 126 · 2012: 130
- FWCI
- 113.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- HDL cholesterol, LDL cholesterol, very low LDL cholesterol, major cardiovascular events, statin therapy, cardiovascular risk prediction, coronary artery disease, myocardial infarction, stroke, low HDL cholesterol
- MeSH terms
- Atorvastatin, Adult, Aged, Anticholesteremic Agents, Apolipoproteins, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Risk, Multivariate Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.